HLB제약 Stock: price and insider trades · South Korea

Every trade that managers of HLB제약 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. 3 insiders have disclosed 9 filings since 18 October 2025.

No insider sold shares on the market over the period. Instead, the filings list 2 purchases, made by 2 insiders. The amount is not disclosed for 2 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 1 chief executive.

Compared with its exchange (2,648 companies, median 7 filings), a count of 9 filings is above the norm. Our records for HLB제약 go back to 2021, with 13 purchases and 1 sale on the open market in total.

The most recent open-market purchase was published on 26 August 2026, 53 days ago. Filings reach the DART (FSS) feed a median of 5 days after the trade. That lag is the time during which only the insider knows about the trade.

For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from DART (FSS). Past trades are no guide to future returns.